Intellia Therapeutics, Inc. (NTLA): Pioneering Gene Editing Solutions for Health Advancements
Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Genmab (GMAB) and Xoma (XOMA)
Maintaining Hold on Intellia Therapeutics Amid Financial Stability and Competitive Pressures
Intellia Therapeutics (NTLA) Receives a Buy From J.P. Morgan
Expert Ratings For Intellia Therapeutics
Express News | JP Morgan Maintains Overweight on Intellia Therapeutics, Lowers Price Target to $55
Buy Rating Affirmed for Intellia Therapeutics Following Successful Phase II Trials and Strong Cash Reserves
Truist Financial Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)
Express News | Intellia Therapeutics Inc : JP Morgan Cuts Target Price to $55 From $61
Intellia Therapeutics, Inc. (NASDAQ:NTLA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Express News | RBC Capital Maintains Outperform on Intellia Therapeutics, Lowers Price Target to $54
Intellia Therapeutics Analyst Ratings
We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully
Evercore ISI Reaffirms Their Buy Rating on Intellia Therapeutics (NTLA)
Intellia Therapeutics: A Strong Buy on Groundbreaking Gene Editing Advances and Positive Clinical Trials
RBC Cuts Price Target on Intellia Therapeutics to $54 From $60, Keeps Outperform, Speculative Risk
Barclays Keeps Their Buy Rating on Intellia Therapeutics (NTLA)
Express News | Intellia Therapeutics Inc : RBC Cuts Target Price to $54 From $60
Intellia Therapeutics | 10-Q: Q2 2024 Earnings Report
Intellia Hereditary Angioedema Candidate Meets Phase 2 Primary Endpoint